The FDA has transferred the Office of Device Evaluation's radiological devices unit to the Office of In Vitro Diagnostic Device Evaluation and Safety in order to address long-term differences in the agency's oversight of in vitro and in vivo diagnostics. The FDA said it expects the move to result in cohesive rules in evaluating diagnostic devices.

Related Summaries